2 Dividend Growth Stocks I'd Buy Right Now

Northrop Grumman (NOC) and Rollins (ROL) are rated Strong Buy for long-term dividend-focused portfolios based on valuation and operating fundamentals. NOC trades at 18x earnings, below peers, supported by diversified defense exposure, backlog growth and rising margins. ROL trades at a two-decade-low 29x multiple, with pricing power and high margins expected to offset near-term housing-market headwinds.

Analysis

NOC's valuation discount is unlikely to close solely on backlog; the rerating catalyst is conversion of classified/program backlog into sustained segment-margin and free-cash-flow guidance upgrades. The key asymmetry is that nuclear modernization and strategic-deterrence programs are politically resilient relative to discretionary defense procurement, but fixed-price execution risk can turn revenue growth into a margin headwind. Over the next 1-3 months, focus on FY guidance cadence and any disclosure around B-21 and Sentinel program economics; over 6-18 months, a cleaner cash-conversion profile could support a multiple closer to large-cap defense peers.

ROL is less a housing beta than a recurring-service density story: slower household formation can delay new-customer additions, but route density, price realization, and retention determine incremental margins. A depressed multiple creates upside if organic growth stabilizes without requiring a housing rebound, while bolt-on acquisition capacity becomes more valuable if smaller operators face financing pressure. The risk is that consumer trade-down or higher customer churn reveals that pricing has been masking weaker unit economics; this would compress the premium multiple further despite the defensive revenue mix.

Consensus may be too quick to group both names as "dividend defensives." NOC has event-driven program and appropriations risk, whereas ROL's primary risk is a gradual de-rating if organic growth remains below its historical algorithm. That argues for owning NOC into identifiable defense-budget/earnings catalysts and treating ROL as a watch-list compounder until evidence of volume stabilization, rather than buying both on valuation narratives alone.

Key Decisions for Investors

• Initiate a 6-12 month long NOC position on weakness ahead of the next earnings release; target a peer-discount narrowing contingent on reaffirmed or improved free-cash-flow guidance. Risk/reward is attractive only if management shows stable program margins; exit or reassess on a material downward revision to cash-flow outlook or a new significant fixed-price charge.
• Use a pair expression: long NOC / short ITA in equal beta-adjusted dollars for 3-6 months. This isolates potential company-specific cash-conversion and valuation catch-up from broad defense-budget moves; close if NOC's relative performance fails to improve following results and forward guidance.
• Do not initiate a full ROL position solely on the low historical multiple. Set an alert for evidence of organic revenue acceleration driven by customer growth/retention rather than price, or for a guidance raise; either would support a 6-18 month long with a catalyst beyond multiple mean reversion.
• For existing ROL exposure, cap sizing until housing-sensitive customer formation and churn data are clearer. A sustained deceleration in organic growth or margin compression despite continued pricing would falsify the defensive-compounder thesis and warrant reducing exposure.